Creative Touch Permanent Makeup and Aesthetics

Pantothenic acid’s role in skin biology is inseparable from its role in Coenzyme A (CoA) synthesis. CoA is the metabolic hub through which fatty acids, ceramides, and sphingolipids are synthesised – the lipid components that constitute the stratum corneum’s waterproof seal and regulate transepidermal water loss (TEWL). Pantothenic acid deficiency measurably impairs keratinocyte proliferation and differentiation, reduces fibroblast production of keratinocyte growth factor (KGF) and procollagen 4a2, and compromises the ceramide biosynthesis that barrier function depends on. ^[5] In aesthetics practice, the clinically relevant form is not pantothenic acid itself but its alcohol derivative – panthenol (D-panthenol, also called dexpanthenol or pro-vitamin B5) – which penetrates the stratum corneum more readily, is converted to pantothenic acid in the viable epidermis, and activates the full downstream CoA-mediated mechanism from inside the tissue. The clinical evidence for topical panthenol covers wound healing acceleration, barrier restoration after chemical or physical disruption, reduction of post-procedure erythema and TEWL, and fibroblast proliferation stimulation – a combination that makes it one of the most consistently useful post-procedure topical agents in the portfolio.

Pantothenic acid is found in virtually all food groups – its name derives from the Greek pantothen (from everywhere) – making frank dietary deficiency rare. In skin biology, however, the relevant question is not simply whether pantothenic acid is present but whether it is available in sufficient quantity at the tissue level to sustain CoA-dependent lipid synthesis at the rate the barrier requires, and whether topical delivery of its pro-vitamin form can meaningfully supplement that availability.

The Pantothenic Acid / Panthenol Distinction

The relationship between pantothenic acid, panthenol, and dexpanthenol is a source of common labelling confusion that we must resolve clearly:

• Pantothenic acid (Vitamin B5) is the biologically active vitamin form – the molecule that cells phosphorylate and incorporate into CoA. It is the oral supplementation form and the nutritional designation.

• Panthenol (pro-vitamin B5) is the alcohol analogue of pantothenic acid – chemically stable, hygroscopic, and more lipid-compatible than pantothenic acid itself, which makes it significantly better suited to topical formulation. On skin contact, panthenol is oxidised by skin oxidases to pantothenic acid in the viable epidermis.

• Dexpanthenol (D-panthenol) is the biologically active enantiomer of panthenol – only the D-form is converted to pantothenic acid; racemic DL-panthenol contains equal D- and L-forms, meaning only half the total panthenol content contributes to the biological mechanism. Products specifying D-panthenol or dexpanthenol deliver twice the active dose per gram compared to DL-panthenol at equivalent label percentage. This distinction is clinically meaningful at higher concentrations (5%+) and is worth understanding when evaluating post-procedure topical formulations.

In INCI ingredient lists: Panthenol covers both D- and DL-forms; Dexpanthenol specifies the active D-enantiomer only. In clinical literature and pharmaceutical formulations, ‘panthenol’ and ‘dexpanthenol’ are used interchangeably to mean the D-form. In INCI ingredient declarations, however, ‘Panthenol’ covers both D- and DL-forms; only ‘Dexpanthenol’ specifies the pure D-enantiomer.

The CoA Pathway: Why B5 Matters for Skin

Coenzyme A is not produced by the skin independently – every molecule of CoA in the epidermis and dermis requires pantothenic acid as its obligate biosynthetic precursor. The pathway: pantothenic acid is phosphorylated by pantothenate kinase to 4′-phosphopantothenate, then converted through four further enzymatic steps to CoA, with ATP providing the adenosyl group at the final step. ^[8]

CoA then functions as the universal acyl group carrier for fatty acid synthesis – ceramide precursors, free fatty acids, and sphingolipids are all assembled through CoA-dependent reactions in differentiating keratinocytes before being packaged into lamellar granules for secretion into the stratum corneum intercellular spaces. ^[4] This means that pantothenic acid availability is a direct upstream determinant of barrier lipid synthesis rate – not a peripheral nutritional consideration but a rate-limiting cofactor in the ceramide and fatty acid assembly process that the Ceramide and Skin Barrier entities describe as the “mortar” of the stratum corneum.

Pantothenic acid deficiency studies in keratinocyte and fibroblast models confirm the clinical consequences: depleted pantothenic acid significantly reduces keratinocyte proliferation and differentiation, reduces fibroblast synthesis of KGF and procollagen 4a2, and compromises the barrier lipid synthesis pathway downstream. ^[5] The corollary – that restoring pantothenic acid availability, particularly in compromised or post-procedure skin where lipid synthesis demand is elevated, improves the rate and quality of barrier repair – is the mechanistic foundation for dexpanthenol’s wound healing evidence.

Wound Healing: The Dexpanthenol Evidence

The most clinically significant evidence base for Vitamin B5 in aesthetics is the post-procedure wound healing literature for topical dexpanthenol. A 2020 review systematically assessed clinical and gene expression evidence for dexpanthenol across superficial wound types relevant to cosmetic and medical interventions – including ablative laser treatment, tattooing, dermabrasion, and skin barrier disruption models. ^[3] Key findings:

• Dexpanthenol upregulates genes critical for the healing process – specifically wound healing cascade genes involved in re-epithelialisation and barrier restoration
• Prospective clinical studies confirmed accelerated re-epithelialisation and faster restoration of skin barrier function following skin injury with topical dexpanthenol vs. untreated controls
• In a tattooing-model RCT (n=54), tattooing induced a 7-fold increase in mean TEWL (significant barrier dysfunction); 5% dexpanthenol water-in-oil application produced virtually complete restoration of barrier function by day 14 – one week earlier than previously reported recovery timelines for untreated chemically disrupted skin ^[3]

The 2025 post-laser panthenol mask RCT adds the most directly applicable data point for the Creative Touch portfolio: a panthenol-enriched mask applied after non-ablative laser treatment significantly improved postoperative skin hydration, enhanced barrier function recovery, and reduced erythema and melanin index at days 3, 7, and 14 compared to controls – with the melanin index reduction at day 14 being of particular clinical relevance for reducing post-procedure dyspigmentation risk. ^[2]

The mechanism behind dexpanthenol’s wound healing acceleration operates through four converging pathways:

1. Fibroblast proliferation stimulation – panthenol directly promotes fibroblast division and migration into the wound bed, increasing the cell population available for collagen synthesis and wound contraction
2. Re-epithelialisation acceleration – keratinocyte proliferation and migration from wound margins is enhanced, shortening the re-epithelialisation phase
3. Anti-inflammatory modulation – reduction of pro-inflammatory cytokines at the wound site, including IL-1α and IL-6 – reducing the inflammatory burden that impedes organised healing
4. Barrier lipid synthesis support – CoA-mediated ceramide and fatty acid production is sustained at elevated demand during barrier repair, providing the lipid substrate for lamellar body secretion and SC reassembly ^[3]

Humectant and Moisturisation Effects

Panthenol is a polyol humectant – its multiple hydroxyl groups bind water molecules in the stratum corneum, increasing SC hydration through the same mechanism as glycerol and propylene glycol. ^[7] A two-part RCT (Tanfonline, 2017) assessed a panthenol-containing emollient in healthy subjects using both a moisturisation model and an SDS-induced barrier disruption model. Results confirmed: significantly improved skin hydration vs. comparator in the moisturisation arm; significantly more rapid and pronounced TEWL reduction in the SDS-disruption recovery arm compared to untreated contralateral skin, reaching statistical significance over a three-week treatment period. ^[6]

The humectant effect and the barrier repair effect are complementary rather than the same mechanism: humectancy increases SC water content acutely through hygroscopic binding; barrier repair restores the lipid matrix that sustains water retention long-term by reducing TEWL. Panthenol delivers both simultaneously – which is what distinguishes it from purely humectant agents (glycerol, hyaluronic acid) that improve hydration without addressing the underlying barrier lipid deficit.

Acne: The Sebum Lipid Hypothesis

The rationale for pantothenic acid in acne management rests on the CoA-fatty acid metabolism pathway. Sebum is produced through CoA-dependent lipid synthesis in sebocytes – the same pathway that produces barrier ceramides. The hypothesis is that when CoA is limiting in sebocyte-rich skin (face, chest, back), available CoA is preferentially directed toward sebum production rather than barrier lipid synthesis; supplementing pantothenic acid increases CoA availability, allowing adequate supply to both pathways and normalising sebum lipid composition. ^[8]

The pivotal clinical test of this hypothesis was a 12-week double-blind, placebo-controlled RCT (PMC4065280, PMID 24831048) of an oral pantothenic acid-based dietary supplement in healthy adults with facial acne. Results: significant reduction in total facial lesion count versus placebo at 12 weeks; significant reduction in area-specific and inflammatory blemishes in secondary analysis. ^[8] The limitations are important: single trial, novel proprietary formulation, and the dose used was substantially higher than standard dietary intake, raising the question of whether the effect is achievable at physiological supplementation levels. The evidence tier is Tier 2 – a single published RCT warranting further independent trials rather than definitive clinical adoption.